Beta Drugs Ratios

Beta Drugs Ltd Ratios

The Beta Drugs Ltd Ratios page provides a complete fundamental analysis of Beta Drugs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Beta Drugs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Beta Drugs Ltd (NSE: BETA, BSE: 535022) is currently trading at ₹1323.70, with a market capitalization of ₹13.29B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Beta Drugs Ltd remains a key stock for fundamental analysis using Beta Drugs Ltd Ratios.

Beta Drugs Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Beta Drugs Ltd P/E ratio currently stands at 46.61, making it one of the most tracked metrics in Beta Drugs Ltd Ratios.

Historically, the Beta Drugs Ltd P/E ratio has shown strong fluctuations:

• 2024: 46.61
• 2023: 32.55
• 2022: 19.62
• 2021: 21.90
• 2020: 9.84

The rising Beta Drugs Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Beta Drugs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 9.76.

Historical P/B trend:

• 2024: 9.76
• 2023: 7.55
• 2022: 4.90
• 2021: 5.89

Beta Drugs Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Beta Drugs Ltd P/S ratio currently stands at 5.46, an important part of Beta Drugs Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.46
• 2023: 4.01
• 2022: 2.66
• 2021: 2.96

The rising Beta Drugs Ltd P/S ratio indicates improved revenue valuation by investors.

Beta Drugs Ltd Price to Cash Flow Ratio (P/CF)

The Beta Drugs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 57.70.

Historical Beta Drugs Ltd Price to Cash Flow Ratio:

• 2024: 57.70
• 2023: 40.63
• 2022: 27.86
• 2021: 19.29
• 2020: 6.99

The rising Beta Drugs Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Beta Drugs Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Beta Drugs Ltd EV currently stands at ₹19.68B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 19.68B
• 2023: 11.72B
• 2022: 6.04B
• 2021: 5.47B

Beta Drugs Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Beta Drugs Ltd EV/EBITDA ratio is currently 26, a key metric in Beta Drugs Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 26
• 2023: 19.53
• 2022: 11.19
• 2021: 12.74

Higher Beta Drugs Ltd EV/EBITDA suggests premium valuation.

Beta Drugs Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Beta Drugs Ltd D/E ratio is currently 0.70, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.70
• 2023: 0.09
• 2022: 0.17
• 2021: 0.22

Beta Drugs Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Beta Drugs Ltd ROE currently stands at 23.95%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 23.95
• 2023: 26.03
• 2022: 28.55
• 2021: 30.85

Beta Drugs Ltd demonstrates strong profitability and efficient capital utilization.

Beta Drugs Ltd Ratios Analysis Summary

The Beta Drugs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Beta Drugs Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Beta Drugs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.